Synthesis and evaluation of sesquiterpene lactone inhibitors of phospholipase A2 from Bothrops jararacussu.
Several sesquiterpene lactone were synthesized and their inhibitive activities on phospholipase A(2) (PLA(2)) from Bothrops jararacussu venom were evaluated. Compounds Lac01 and Lac02 were efficient against PLA(2) edema-inducing, enzymatic and myotoxic activities and it reduces around 85% of myotoxicity and around 70% of edema-inducing activity. Lac05-Lac08 presented lower efficiency in inhibiting the biological activities studied and reduce the myotoxic and edema-inducing activities around only 15%. The enzymatic activity was significantly reduced. The values of inhibition constants (K(I)) for Lac01 and Lac02 were approximately 740 μM, and for compounds Lac05-Lac08 the inhibition constants were approximately 7.622-9.240 μM. The enzymatic kinetic studies show that the sesquiterpene lactones inhibit PLA(2) in a non-competitive manner. Some aspects of the structure-activity relationships (topologic, molecular and electronic parameters) were obtained using ab initio quantum calculations and analyzed by chemometric methods (HCA and PCA). The quantum chemistry calculations show that compounds with a higher capacity of inhibiting PLA(2) (Lac01-Lac04) present lower values of highest occupied molecular orbital (HOMO) energy and molecular volume (VOL) and bigger values of hydrophobicity (LogP). These results indicate some topologic aspects of the binding site of sesquiterpene lactone derivatives and PLA(2).
Depto de Química, Universidade Federal de Viçosa - UFV, Viçosa, MG, Brazil. elson@ufv.br
E S
ES
de Alvarenga
S A
SA
Silva
L C A
LC
Barosa
A J
AJ
Demuner
A G
AG
Parreira
R I M A
RI
Ribeiro
S
S
Marcussi
J M S
JM
Ferreira
R R
RR
Resende
P A
PA
Granjeiro
J A
JA
Silva
A M
AM
Soares
S
S
Marangoni
S L
SL
Da Silva
D000818:Animals; D001665:Binding Sites; D017837:Bothrops; D003435:Crotalid Venoms / Q000737:chemistry; D004336:Drug Antagonism; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology*; D006614:Hindlimb; D007273:Injections, Intramuscular; D007783:Lactones / Q000138:chemical synthesis / Q000494:pharmacology; D008297:Male; D051379:Mice; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D009336:Necrosis / Q000139:chemically induced / Q000473:pathology; D064801:Phospholipase A2 Inhibitors; D054467:Phospholipases A2 / Q000302:isolation & purification; D045787:Sesquiterpenes, Eudesmane / Q000138:chemical synthesis* / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D003435:Crotalid Venoms; D004791:Enzyme Inhibitors; D007783:Lactones; D064801:Phospholipase A2 Inhibitors; D045787:Sesquiterpenes, Eudesmane; D054467:Phospholipases A2